Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo

Trial Profile

A Randomised, Double-blind, Placebo-controlled Study, in COPD Patients With and Without a Confirmed Respiratory Virus Infection Assessing Anti-viral Biomarker Responses and Clinical Effects of Inhaled SNG001 Compared to Placebo

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Synairgen
  • Most Recent Events

    • 27 Dec 2018 Planned number of patients changed from 260 to 190.
    • 27 Dec 2018 Status changed from active, no longer recruiting to recruiting.
    • 22 Oct 2018 According to a Synairgen media release, dosing has commenced in Part 2 of this trial. The aim of Part 2 is to study the efficacy and safety of inhaled SNG001 in up to 120 COPD patients with a confirmed respiratory viral infection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top